


































New Medicines in Wales





Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Varnava, A., Samuels, K., Hughes, D., & Routledge, P. A. (2018). New Medicines in Wales: The
All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Pharmacoeconomics, 36(5), 613-624. https://doi.org/10.1007/s40273-018-0632-7
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 01. Jun. 2021
ORIGINAL RESEARCH ARTICLE
New Medicines in Wales: The All Wales Medicines Strategy
Group (AWMSG) Appraisal Process and Outcomes
Alice Varnava1 • Robert Bracchi1 • Karen Samuels1 • Dyfrig A. Hughes2 •
Philip A. Routledge1
 The Author(s) 2018. This article is an open access publication
Abstract
Background The All Wales Medicines Strategy Group
(AWMSG) develops prescribing advice and is responsible
for appraising new medicines for use in Wales. In this
article, we examine the medicines appraisal process in
Wales, its timeliness and its impact on medicines avail-
ability in Wales, and compare its processes and recom-
mendations with the two other UK health technology
appraisal bodies [the National Institute for Health and Care
Excellence (NICE) and the Scottish Medicines Consortium
(SMC)].
Methods We reviewed the medicines appraisals conducted
by AWMSG between October 2010 and September 2015.
The duration of the process and the recommendations made
by AWMSG were compared with those of NICE and SMC.
Only publicly available data were considered in this
review.
Results AWMSG conducted 171 single technology
appraisals for 137 medicines during the study period (34
were for medicines previously appraised by AWMSG but
these were for new indications). Of these, 152 appraisals
were supported for use in NHS Wales (33 with restrictions)
and 19 were not supported. Recommendations broadly
concurred with SMC and NICE for the majority of
appraisals. Compared with NICE recommendations, the
median time advantage gained in Wales for those
medicines that received a positive AWMSG recommen-
dation and which were subsequently superseded by NICE
advice was 10.6 months (range 3.5–48.3 months; n = 17).
Conclusion This review highlights the work carried out by
AWMSG over a 5-year period, and provides evidence to
support the effectiveness of the appraisal process in terms
of patients in Wales gaining earlier access to medicines and
efficiency through reduced duplication with NICE.
Key points for Decision Makers
From October 2010 to September 2015, the All
Wales Medicines Strategy Group (AWMSG)
conducted 171 appraisals of 137 medicines; a
positive recommendation, with or without
restrictions, was given in 88.9% of appraisals.
The decisions made by AWMSG and two other UK
health technology assessment (HTA) organisations
for the same medicines/indications were closely
aligned.
Patients in Wales gained a 10-month median
advantage (range 3.5–48.3 months) over those in
England for medicines that received a positive
AWMSG recommendation and which were
subsequently superseded by a positive
recommendation by the National Institute for Health
and Care Excellence (NICE).& Alice Varnava
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Since political devolution in 1999, governments across the
UK each have control over the level of funding, and the
structure and governance, of the National Health Service
(NHS) available to their residents. In 2015–2016, the
Welsh Government spent £6.7 billion on health [1], rep-
resenting approximately 12% of gross value added in
Wales (2015) [2]. The total spend on prescribed medicines
in primary healthcare was £518 million [1]; 7.7% of the
NHS expenditure. In the community, Wales dispensed the
highest number of prescription items per head per annum
among the four devolved countries: 25.7 compared with
21.6 in Northern Ireland, 20.0 in England and 19.0 in
Scotland [3].
With a fixed budget [4], each country seeks to achieve
best value via established health technology assessment
(HTA) bodies which evaluate medicines for their clinical
and cost effectiveness. The Scottish Medicines Consortium
(SMC) evaluates all authorised medicines submitted to it;
in England, the National Institute for Health and Care
Excellence (NICE) appraises new medicines referred to it
by the Department of Health; and in Wales, the All Wales
Medicines Strategy Group (AWMSG) adopts NICE guid-
ance where available and appraises the remaining new
medicines not on the NICE work programme. Northern
Ireland does not have its own comparable HTA agency so
has not been included in this review.
AWMSG was established by the Welsh Government in
2002, as a statutory scientific advisory committee, to pro-
vide advice on medicines management and prescribing to
the then Minister for Health and Social Services (now the
Cabinet Secretary for Health and Social Services).
AWMSG consists of NHS clinicians, pharmacists, health-
care professionals, academics, health economists, industry
representatives and patient advocates, whose aim is to
reach a consensus on the use of medicines within primary
and secondary care [5]. The work of AWMSG can be
broadly categorised as appraising new medicines, and
issuing prescribing and medicines optimisation advice.
These activities are the concerns of two subgroups: the
New Medicines group (NMG), which considers the clinical
and economic evidence on new medicines, and which
provides preliminary recommendations to AWMSG on the
introduction of new medicines in Wales; and the All Wales
Prescribing Advisory Group which advises AWMSG on
strategic developments in primary and secondary care
prescribing. The latter group assists with monitoring pre-
scribing, advising on prescriber training, and developing
prescribing indicators and audits for a national incentive
scheme.
In this article, we focus on the AWMSG process for
appraising new medicines, review its achievements in
terms of appraisal recommendations and compare out-
comes with those of the other two HTA bodies in the UK:
NICE and SMC.
1.1 Appraisals Process
The AWMSG appraisal programme provides recommen-
dations based on the clinical and cost effectiveness of new
medicines and new indications via a transparent and evi-
dence-based process. The original remit of the AWMSG
appraisal process was focused on high-cost medicines (i.e.
those costing[ £2000 per patient per year). In April 2007,
the AWMSG appraisal process was broadened to also
include all new cardiovascular and cancer medicines, in
response to clinical service need. Since October 2010, the
remit has been further expanded to include all new
medicines that are not on the 12-month work programme of
NICE [6]. AWMSG therefore considers medicines that are
not appraised by NICE and those for which a final NICE
appraisal is not expected for a considerable time. Should
NICE issue guidance subsequently, however, its final
technology appraisal advice supersedes AWMSG recom-
mendations. If a medicine has not been recommended for
routine use in Wales, a request for access to the medicine
can be made through the individual patient funding pro-
cess, or through the One Wales Interim Pathways com-
missioning route [7, 8].
Whereas NICE assesses selected medicines and other
health technologies, and operates two appraisal methods
(single and multiple technology appraisals), both AWMSG
and SMC conduct single technology appraisals of all
medicines. AWMSG, unlike SMC, is aligned with NICE in
that Welsh health boards have a legal requirement to
implement NICE and AWMSG guidance within a given
timeframe [9]. This means that NHS Wales benefits from
formal, robust evaluation of a wide range of medicines,
including treatments such as those for HIV and rare
diseases.
AWMSG considers either a full or limited submission
from a marketing authorisation holder (MAH): limited
submissions are for new formulations, minor license
extensions of existing medicines (e.g. use in paediatrics), if
the anticipated usage in NHS Wales is considered to be of
minimal budget impact, or if the estimated difference in
cost compared with relevant comparator(s) is small. There
is no explicit threshold for what is considered a minimal
budget impact or small difference in cost: these are
assessed on a case-by-case basis by the AWMSG secre-
tariat. SMC has a similar approach; full or abbreviated
submissions, where the latter is for consideration of new
formulations and minor license extensions [10]. In contrast,
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health technologies referred to NICE for appraisal are
prioritised, with only about 40% of all new medicines
appraised in 2012 [11]. NICE aims to consider all new
significant medicines and indications: new formulations
and minor license extensions are not normally appraised by
NICE [12, 13].
A summary of the AWMSG appraisal process and
schedule are outlined in Fig. 1 [14]. The process used by
AWMSG to produce Final Appraisal Recommendations
(FARs) for the Welsh Government was awarded NICE
accreditation in 2011 for 5 years and was reaccredited in
October 2016 for a further 5 years [15]. The secretariat arm
of AWMSG, the All Wales Therapeutics and Toxicology
Centre (AWTTC), initially suggests the appraisal scope
and informs the MAH whether a full or limited submission
is required. Following an initial review of the submission
for completeness and appropriateness, and clarification of
the scope from AWTTC or the MAH, the scope and
schedule are confirmed. AWTTC aims to process an
application (full or limited) within 6 months of the sub-
mission being received.
Following confirmation of the scope and schedule,
AWTTC produces a report (AWMSG Secretariat Assess-
ment Report [ASAR]). The AWTTC, consisting of phar-
macists, clinical pharmacologists, health economists and
appraisal scientists, assesses the clinical efficacy, compar-
ative safety, cost effectiveness and likely budget impact of
a new medicine. The secretariat summarises and critiques
the evidence submitted by the MAH and evidence found in
other relevant publicly available material when compiling
the ASAR. Evidence from reviews of the literature, con-
ducted by AWTTC, is also considered and incorporated
into the ASAR if deemed relevant. The assessment process
encompasses a critical evaluation of the clinical evidence,
including any quantitative evidence synthesis conducted by
the MAH; a detailed interrogation of the economic and
budget impact models, with alternative scenarios and
analyses conducted if considered appropriate, and com-
ments on the plausibility of alternative scenarios. The
AWTTC has about 4 weeks to complete an ASAR, which
allows for data to be verified (e.g. checking the economic
model sensitivity to changes in key inputs), expert clinical
opinion to be elicited and clinical evidence to be sum-
marised and critiqued. Relevant clinical experts and patient
organisations are identified and their views solicited in a
questionnaire: clinical experts must declare any interests;
individual patients and carers can also comment using a
questionnaire available on the AWMSG website [16, 17].
The ASAR is sent to the MAH for comment and, on return,
AWTTC considers the responses and the ASAR may be
amended.
Approximately 3 months after the scope is agreed, NMG
members meet in private to discuss the submission and
make a Preliminary Appraisal Recommendation (PAR)
based on the ASAR, MAHs’ comments on the ASAR,
clinical expert opinion, and the views of patients, carers
and patient organisations. Approximately 1 month later,
this is considered, in turn by AWMSG, which additionally
considers equity, broader societal issues and the budget
impact of the new medicine in Wales. A FAR is agreed by
the AWMSG members and submitted to the Welsh
Government for ratification. If the MAH disagrees with the
AWMSG recommendation, they may request an indepen-
dent review to address complaints in relation to process
and/or scientific issues: for example, the MAH may feel
that insufficient time or opportunity was given for discus-
sion of relevant issues, and/or there has been a misinter-
pretation of information [18].
AWMSG has always held its meetings in public to
ensure the transparency of the decision-making process.
The ASAR, the PAR, comments from the MAH on the
PAR and a summary of clinical experts’ opinions are
posted on the AWMSG website prior to the AWMSG
public meeting.
Although the onus for engagement with the AWMSG
process lies with the MAH, AWTTC horizon scanning
helps to identify medicines expected to receive their mar-
keting authorisation (MA; product licence) within 18
months and will alert the MAH to the appraisal process
[19]. Should the MAH fail to engage, and choose not to
submit any evidence in support of their medicine, AWMSG
will either issue a Statement of Advice confirming the
medicine cannot be endorsed for use within NHS Wales,
or, when directed to do so by the AWMSG Steering
Committee, will appraise the medicine using publicly
available information [19].
1.2 Appraisal Criteria
The criteria by which NMG and AWMSG appraise
medicines are mainly aligned with those of NICE and SMC
[20–22]. The determination of clinical effectiveness allows
for proportionate consideration of different hierarchies of
evidence. This is consistent with a view that diverse forms
of evidence serve different purposes [23].
AWMSG judgments on the cost effectiveness of new
medicines are made on the basis of the incremental cost per
quality-adjusted life-year (QALY) gained. Economic evi-
dence is normally derived from a model which synthesises
the available evidence to assess the expected costs and
QALY gains over an appropriate time horizon. This is
normally a lifetime horizon for treatments for chronic
diseases or which impact on survival. Medicines deter-
mined to be clinically effective, and whose incremental
cost-effectiveness ratios (ICERs) are below £20,000 per
QALY, are normally recommended for use; with an ICER
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between £20,000 and £30,000 per QALY, judgments on
their acceptance are based on the level of certainty in the
ICER, the innovative nature of the medicine and the nature
of the disease being treated. Above an ICER of £30,000 per
QALY gained, the case for supporting a medicine on these
factors has to be increasingly strong [20].
Clinical experts 
identified and asked 
for their views.
Receipt of full or limited submission and confirmation of EMA 
positive opinion within 3 months of receipt of product license. 





present PAR to AWMSG.
ASAR sent to MAH for comment. Written response returned 
within 10 working days.
Patient organisations 
identified and asked 
for their views. 
Individual patients 
and carers can also 
comment.
ASAR prepared by AWTTC. Summarises and critiques 
evidence submitted by MAH.
Appraisal documents (final ASAR, PAR, MAH response to 
the PAR and CE summary posted on AWMSG website 
approximately 10 days prior to public meeting.
PAR sent to MAH for comment. Written response returned 
within 5 working days. PAR will not be amended.
MAH response to the ASAR considered by AWTTC (ASAR 
may be amended). Process proceeds regardless of whether 
response received.
Upon confirmation of Ministerial ratification of FAR: MAH
informed; email communication disseminated to service; 
FAR posted on AWMSG website.
AWMSG recommendation (FAR) sent to Welsh Government 
for ratification (subject to request for independent review).
Documents sent to NMG members: ASAR, MAH response to 
the ASAR, original submission, CE opinion and patient 
perspective.
NMG MEETING
Documents considered by NMG members. PAR agreed.
AWMSG MEETING
ASAR, PAR, MAH response to the PAR, CE summary, 
societal impact, budget impact and patient perspective 
considered by AWMSG. AWMSG recommendation agreed 
and announced.
MAH given 10 working days to 
accept/reject AWMSG recommendation.
FAR approved by AWMSG Chair.
Fig. 1 Summary of medicines appraisal process in Wales by the All
Wales Medicines Strategy Group (AWMSG) [14]. ASAR, AWMSG
Secretariat Assessment Report; AWTTC, All Wales Therapeutics and
Toxicology Centre; CE, clinical expert; EMA, European Medicines
Agency; FAR, Final Appraisal Recommendation; MAH, marketing
authorisation holder; NMG, New Medicines Group; PAR, Preliminary
(to AWMSG) Appraisal Recommendation
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The end-of-life criteria developed by NICE apply for
medicines that are indicated for terminal diseases (life
expectancy normally less than 2 years), whose ICERs
exceed £30,000 per QALY, and which are expected to
generate survival benefits of at least 3 additional months. In
such cases, AWMSG is able to apply greater moderation in
its assessment of their cost effectiveness. AWMSG asses-
ses the impact of giving more weight to QALYs achieved
in the later stages of terminal diseases, and of the magni-
tude of the additional weight that would need to be
assigned to the QALY benefits in this patient group for the
cost effectiveness of the medicine to fall within the current
threshold range [24]. However, there is no explicit maxi-
mum allowable weighting, offering AWMSG members
flexibility to enable medicines such as abiraterone
(Zytiga) for the treatment of prostate cancer, which
otherwise may not be deemed to be cost effective, to be
recommended for use in Wales [25]. SMC uses broader
end-of-life criteria; an end-of-life medicine is defined by
SMC as one used to treat a condition at a stage that usually
leads to death within 3 years with currently available
treatments [26].
AWMSG and SMC have specific policies for orphan and
ultra-orphan medicines [26–28]. An orphan medicine is
defined as a medicine with orphan status as designated by the
European Medicines Agency, which includes conditions
affecting not more than 5 in 10,000 persons. An ultra-orphan
medicine is a medicine that has been designated orphan
status by the European Medicines Agency and is used to treat
a condition with a prevalence of 1 in 50,000 or less in the UK.
The AWMSG [27] and SMC [26] policies enable access to
such treatments, which invariably exceed the cost-effective
threshold, following a commitment to the non-abandonment
of individuals with needs for highly specialised treatments
[29]. NICE considers medicines for very rare conditions
separately from the HTA process and via their highly spe-
cialised technology evaluation process [30].
A further appraisal consideration distinguishing
AWMSG from NICE is the assessment of budget and wider
societal impacts [20]. Medicines with a large budget
impact will be associated with significant opportunity cost
if an incorrect appraisal recommendation is made. Thus,
AWMSG will need to be more certain of the ICER esti-
mates when the budget impact is considered to be large.
SMC also considers budget impact and the wider issues
that go beyond the scientific arguments [31].
2 Methods
All medicines appraised by AWMSG from October 2010 to
September 2015 inclusive were reviewed. The dataset was
restricted to a recent 5-year period when AWMSG
processes and appraisal criteria were stable. Only publi-
cally available data from AWMSG [32], NICE [33] and
SMC [34] were considered in this review.
The approved therapeutic indication for each medicine
at the time of the appraisal was recorded, as well as the
medicine’s categorisation according to the British National
Formulary (BNF), and whether or not the medicine had
ultra-orphan status. All appraised medicines were cate-
gorised according to the AWMSG final recommendation: a
positive recommendation, a positive recommendation with
restrictions (referred to as an optimised recommendation
by NICE) or a negative recommendation. A restricted
recommendation is given when the use of the medicine is
restricted to a sub-population of the full indication under
consideration.
The number of independent reviews during this period
was recorded, as was the number of positive recommen-
dations based on a resubmission after an initial negative
recommendation from AWMSG, and instances when the
MA had been withdrawn after the appraisal had been
completed. The number of Statements of Advice was
recorded for those medicines that were subsequently
appraised by AWMSG during the 5-year period.
The duration of the HTA process in Wales was mea-
sured as the time from (1) the European Medicines Agency
MA to receipt of a MAH submission by AWTTC; (2)
AWTTC sending the final appraisal scope to the MAH, to
the AWMSG meeting when the recommendation is agreed
and announced; (3) MA to the AWMSG meeting; and (4)
MA to final decision by the Welsh Government (i.e. min-
isterial ratification).
The recommendations for the medicines that were also
appraised by NICE and/or SMC were reviewed and com-
pared with the AWMSG recommendations, as were the
times from MA to advice being published.
The primary aim of this study is to describe the
AWMSG HTA process and highlight the recommendations
made by the three organisations; therefore, descriptive
statistics are reported. Statistical analyses using Wilcoxon
matched pairs signed rank tests were carried out to com-
pare (1) the time it takes for AWMSG and NICE or SMC to
process an appraisal (MA to recommendation); and (2) the
time it takes for patients in Wales (MA to ministerial rat-
ification), England and Scotland (MA to guidance) to have
access to the same medicines. AWMSG and SMC time to
event data were not normally distributed; therefore, the
non-parametric analyses (Wilcoxon) were carried out. In
all cases, p\0.05 was taken as the minimum level of
statistical significance.
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3 Results
3.1 All Wales Medicines Strategy Group (AWMSG)
Appraisal Recommendations
Between October 2010 and September 2015, AWMSG
conducted 171 appraisals of 137 medicines; 34 of these 171
appraisals were of new indications for medicines previ-
ously appraised by AWMSG. Of the 171 appraisals, 119
(69.6%) received a positive recommendation, 33 (19.3%)
received a positive recommendation with restrictions and
19 (11.1%) received a negative recommendation. Of the
latter category, six subsequently received a positive rec-
ommendation (with or without restriction) based on
resubmissions; in the case of one (tacrolimus [Advagraf]),
two negative recommendations were issued prior to a
restricted recommendation being made [35]. Additionally,
the marketing licence was withdrawn from two products
(ferumoxytol [Rienso], recommended with restrictions;
colestilan [BindRen], not recommended) after the
appraisal had been completed [36, 37]. Of the 171
medicines appraised, 56 (32.7%) were previously given a
Statement of Advice due to the MAH not engaging in the
appraisal process within 3 months of MA; the Welsh
Government directed AWMSG to appraise one of these
medicines (fampridine [Fampyra]) using publicly avail-
able information [38]. One appraisal was taken to the
Independent Review Panel (pazopanib [Votrient] was not
recommended by AWMSG); the MAH had expressed
concerns in relation to the interpretation of the evidence.
The grounds for review were upheld and AWMSG reap-
praised the product taking into account the issues raised in
the independent review, and subsequently recommended it
as an option for use [39].
A breakdown of appraisal outcome by BNF chapter is
provided in Table 1. AWMSG most commonly appraised
products for the treatment of HIV and made positive rec-
ommendations (with or without restrictions) for all 20
treatments. Of the 171 appraisals completed by AWMSG,
four were of ultra-orphan medicines, all of which were
recommended for use in NHS Wales (one with
restrictions).
3.2 Duration of AWMSG Process
The median time from MA to receipt of an MAH sub-
mission by AWTTC was 4.9 months (range 7 days to 56.4
months; n = 132). A total of 39 appraisals had been
excluded from analysis. There was no scope date and/or
submission date available for 29 of 171, and for nine of 171
the MA was received after submission to AWTTC. One of
the 171 was excluded because it underwent an independent
review.
The median time from the final scope being sent to the
MAH and the AWMSG meeting was 4.2 months (range
2.6–8.3 months; n = 156). Fifteen of the 171 appraisals
were excluded from analysis because there was no scope
date available.
The median time from MA to AWMSG recommenda-
tion was 9.7 months (range 2.7–61.2 months; n =140). A
total of 31 of the 171 appraisals were excluded from
analysis. One went through independent review and one
went through re-appraisal. A further 29 were excluded
because no MA date was available.
3.3 Comparison with the National Institute
for Health and Care Excellence (NICE)
and Scottish Medicines Consortium (SMC)
The outcomes from appraisals undertaken by AWMSG and
NICE were closely aligned: the two organisations agreed
on 87.0% (20/23) of appraisal recommendations. Of 151
appraisals where use of the product was supported by
AWMSG (with or without restrictions), NICE did not
schedule 120 (79.5%) for appraisal, subsequently recom-
mended 17 (11.3%), did not recommend two (1.3%), sus-
pended one (0.7%), discontinued three (2.0%) and, as of
May 2017, were still in the process of appraising eight. Of
the 18 products not supported by AWMSG, NICE did not
schedule 13, subsequently recommended one, did not rec-
ommend three, did not suspend or discontinue any and
were in the process of appraising one.
The outcomes from appraisals undertaken by AWMSG
and SMC were closely aligned: they agreed on 87.8% (130/
148) of appraisal recommendations. Of 169 appraisals
undertaken by AWMSG, only 16 (9.5%) had not been
scheduled for appraisal by SMC. Of 135 products sup-
ported by AWMSG, 119 (88.2%) were recommended by
SMC (with or without restrictions) and 16 (11.8%) were
not recommended (two due to non-submission). Of the 18
products not supported by AWMSG, five were recom-
mended by SMC (with or without restrictions) and 13 were
not recommended (three due to non-submission).
The median time from MA to NICE recommendation
(27.5 months; mean 29.3 months; range 9.7–70.9 months)
was significantly longer than when the same medicines
were appraised by AWMSG (11.5 months; mean 13.9
months, range 4.7–47.9 months; n = 23; p\0.0001). The
median time from MA to NICE recommendation was also
significantly longer than when the same medicines were
appraised by AWMSG and subsequently ratified by Welsh
Government (12.6 months; mean 15.7 months; range
5.4–49.2 months; n = 23; p = 0.0004).
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Table 2 shows the time advantage gained for patients in
Wales for those medicines that received a positive
AWMSG recommendation (with or without restrictions)
and that were subsequently superseded by a positive rec-
ommendation from NICE. The median time gained in
Wales was 10.6 months (mean 17.7 months; range 3.5–48.3
months; n = 17; p = 0.0003).
The median time from MA to SMC recommendation
(7.7 months; mean 10.1 months; range 2.5–52.2 months)
was significantly shorter than when the same medicines
were appraised by AWMSG (10.4 months; mean 14.1
months; range 2.7–61.2 months; n = 127; p\0.0001) or
ratified by the Welsh Government (11.9 months; mean 15.6
months; range 3.9–62.2 months; n = 127; p\0.0001).
4 Discussion
Between October 2010 and September 2015, AWMSG
provided guidance on 171 indications for 137 medicines,
89% of which were given positive recommendations (ei-
ther in full or with restrictions). For the majority of these
medicines (80%) there would otherwise have been no
national guidance in Wales as these were outside the scope
of NICE. Four were for ultra-orphan medicines, and while
the data are sparse and often involve surrogate outcomes,
the AWMSG ultra-orphan medicines policy worked to
facilitate patient access to medicines for some of the rarest
diseases.
The time from MA to AWMSG recommendation was
short compared with NICE (11.5 vs. 27.5 months), and
since the Welsh health boards had a legal obligation to
implement guidance within 3 (changed in 2017 to 2)
months, patients in Wales had quick access to those
Table 1 Breakdown of the All Wales Medicines Strategy Group appraisal outcome by British National Formulary chapter and subsection, and
orphan status






All AWMSG appraisals 171 119 33 19
Orphan status
Ultra-orphan medicinesa 4 3 1 0
Non-ultra-orphan medicinesa 167 116 32 19
BNF chapter/subsection
1. Gastrointestinal system 4 2 1 1
2. Cardiovascular system 13 9 2 2
3. Respiratory system 13 12 0 1
4. Central nervous system 16 11 3 2
5. Infections 36 28 8 0
5.3.1. HIV infectionb 20 19 1 0
6. Endocrine system 19 13 3 3
6.1.2. Antidiabetic drugsb 13 9 3 1
7. Obstetrics, gynaecology, and urinary-tract
disorders
3 3 0 0
8. Malignant disease and immunosuppression 33 20 6 7
8.1.5. Other antineoplastic drugsb 17 10 4 3
9. Nutrition and blood 11 6 4 1
10. Musculoskeletal and joint diseases 15 10 4 1
11. Eye 2 1 0 1
12. Ear, nose, and oropharynx 0 0 0 0
13. Skin 4 2 2 0
14. Immunological products and vaccines 0 0 0 0
15. Anaesthesia 2 2 0 0
AWMSG All Wales Medicines Strategy Group, BNF British National Formulary
aMedicines classed as either ultra-orphan or non-ultra-orphan by AWMSG
bOnly the BNF subsections where most AWMSG appraisals have been undertaken have been included for comparison
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medicines judged to be clinically and cost effective.
Patients in Wales also gained a significant 10-month
median advantage (range 3.5–48.3 months) over those in
England for medicines which first received a positive
AWMSG recommendation and which were subsequently
superseded by a positive recommendation from NICE.
Between 2000 and 2017, NICE recommended (either in
full, or optimised) 548 (81%) of the technologies it
appraised [40]. The higher rate in our sample of AWMSG
appraisals (89%) may be explained in part by the exclusion
of medicines not imminently considered by NICE. The
limited overlap between NICE topic selection and
medicines/indications eligible for AWMSG appraisal
means agreement rates are not directly comparable.
There was strong agreement in recommendations
between AWMSG and NICE (87.0%) or SMC (87.8%)
among the comparable samples analysed. It is possible that
disagreements are a result of differences in the evidence
submitted by the MAH to the organisations. Of the 151
appraisals where use of the medicine was supported by
AWMSG, NICE subsequently did not recommend two for
routine use within NHS England and Wales. AWMSG’s
existing recommendation is normally superseded by NICE
guidance and therefore, in these circumstances, the medi-
cine would not be prescribed routinely within NHS Wales.
However, patients in Wales who are currently being treated
with a medicine, following a positive recommendation
from AWMSG, should have the option to continue their
therapy until they and their clinicians consider it appro-
priate to stop. The opportunity costs of patients having
access to medicines that are then not deemed cost effective
are considered by AWMSG when making their decisions.
The time it took from MA to recommendation for the
same medicines to be appraised by AWMSG was signifi-
cantly shorter than by NICE but longer than by SMC.
AWMSG’s relatively short decision time is despite nearly a
third of MAHs engaging with the AWMSG process more
than 3 months after MA. However, there are confounding
factors outside the control of the HTA agency that may
affect timelines: for example, the MAH may submit an
application to one HTA body and then to another at a later
date; or the MAH may submit different evidence to each
body. Furthermore, given the avoidance of duplication
between AWMSG and NICE appraisal activities, medici-
nes appraised by both organisations will naturally be those
for which there is a delayed NICE appraisal, and the time
advantage may therefore not be generalised across all
appraisals. The timeline of the NICE HTA process, inde-
pendent from AWMSG, has been considered previously.
Single technology appraisals—a process appraising a sin-
gle product with a single indication—takes NICE approx-
imately 9–12 months to complete [41]. However, there is
variability throughout the years; for example, in 2009, the
median time to publication was 8 months (range
4–38 months), but in 2010 the median time was 29 months
(range 4–30 months) [42]. Lengthier times for NICE
guidance may partly be due to measures to provide trans-
parency and the widespread consultation during the NICE
process [42].
In this study we restricted the dataset to a 5-year period
during which AWMSG processes and appraisal criteria
were stable. AWMSG was established in 2002; however,
data on pre-2010 and post-2015 appraisals were not
included as there were several significant changes to the
AWMSG processes and appraisal criteria during these
periods. For example, changes were made to the way
AWMSG appraises orphan and ultra-orphan medicines and
medicines developed for rare diseases in 2016, giving
patients and clinicians a stronger voice in AWMSG deci-
sion-making. We are unaware of significant analogous
changes at NICE or SMC; however, it is possible that
changes in their policies may have had an effect on our
comparisons.
This is the first systematic description of AWMSG’s
decisions and comparison with other UK HTA decisions.
However, there are several equivalent studies of the pro-
cesses and decisions made by NICE [43–45], SMC [46]
and the National Centre for Pharmacoeconomics in Ireland
[47], as well as other European countries [48]. An analysis
of recommendations given by AWMSG reported that 59%
of orphan medicines were given a positive recommenda-
tion (with or without restrictions) while 73% of ultra-or-
phan medicines were recommended [49]. A comparative
analysis of orphan medicines reimbursement in the UK and
other European countries between 2000 and 2016 reported
that access was particularly slow in Wales [48]. However,
this latter study included the time it takes the MAH to
make a submission to AWTTC, and because of the align-
ment of AWMSG and NICE processes, the MAH often
waits for a decision from NICE on whether it will appraise
before engaging with the process in Wales. This time-lag
due to the MAH submitting first to NICE makes the
AWMSG process appear longer when measured from MA
to recommendation or MA to ratification. Although the
onus is on the MAHs to provide the information needed to
appraise the medicine, AWTTC continues to liaise closely
with them to encourage them to submit earlier.
Factors which influence the recommendations made by
AWMSG, and its subcommittee NMG, have been consid-
ered previously [50]. An analysis of appraisal decisions
made between 2007 and 2009 revealed a preference for
medicines supported by a greater body of clinical evidence,
and that consideration of combined uncertainty in eco-
nomic model parameters had a positive influence on the
recommendations of NMG and AWMSG [50]. Further-
more, ICERs for medicines with negative
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recommendations were, on average, higher than for
medicines with positive recommendations; this is consis-
tent with the pursuit of economic efficiency [50]. A stated
preference study using a discrete choice experiment of
committee members found that the incremental cost
effectiveness of new medicines, and the QALY gains they
provide, influences decisions to varying degrees depending
on whether or not the uncertainty in cost effectiveness has
been thoroughly explored, and whether or not the primary
impact of the disease is on survival or quality of life [51].
The willingness to trade the cost effectiveness and QALY
gains against these other factors indicates that economic
efficiency and QALY maximisation are not the only con-
siderations AWMSG takes into account when making
recommendations [51].
The findings of the present review highlight the effi-
ciency of the appraisal process in Wales through reduced
duplication with NICE, and demonstrate the advantage to
patients in earlier access to medicines. Whilst direct evi-
dence of the impact of AWMSG on the health of the
population in Wales is unattainable at present, uniform and
expedited advice on non-NICE-appraised medicines (and
treatments not scheduled to be appraised by NICE) to the
NHS in Wales has resulted in more rapid and
equitable access to new medicines. The low number of
appraisals undertaken by both AWMSG and NICE
(n = 23) over the 5-year study period demonstrates a low
level of duplication of work from the two organisations
(AWMSG has had an agreed Memorandum of Under-
standing with NICE since 2012, which was renewed in
October 2016 for another 5 years).
Evolving challenges have included the growing number
of orphan drugs. In response to its appraisal of ivacaftor
(Kalydeco), a treatment for cystic fibrosis, AWMSG
changed its orphan drugs policy to enable even greater
involvement of patients and clinicians in the decision-
making process [27, 52]. Meanwhile, NICE has recently
introduced new guidelines for appraising highly specialised
technologies [30], the outcome of which are adopted by
AWMSG, and a fast-track process for technologies that are
considered to offer exceptional value for money [53].
NICE have also introduced a budget impact test to assess
the financial impact of a technology over the first 3 years of
its use in the NHS [54]. In order to increase access to high-
cost treatments, AWMSG has adopted its own Wales
Patient Access Schemes, but whereas pricing has been (and
will continue to be) set at a UK level, HTA is a matter for
the devolved governments, and the relationship between
the three HTA organisations and the ‘pricing unit’ has yet
to be clarified [55]. A further challenge to AWMSG is the
increased need for the opportunity cost to be estimated. It is
important to identify what is foregone when new cost-
increasing technologies are introduced to understand the
effects of HTA decisions on the healthcare system [56, 57].
5 Conclusion
This article highlights the HTA work carried out by
AWMSG over a 5-year period. We demonstrate the effi-
ciency of the appraisal process in Wales and compare it
with the analogous HTA processes in England and
Scotland.
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